Ardelyx (41X) Stock Forecast & Price Target

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

41X Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Ardelyx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

41X Stock 12 Month Forecast

Average Price Target

€14.65

▲(228.57% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is €14.65 with a high forecast of €16.71 and a low forecast of €13.19. The average price target represents a 228.57% change from the last price of €4.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","17":"€17","5.75":"€5.75","9.5":"€9.5","13.25":"€13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.70576406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.654179,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€14.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.1887611,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.75,9.5,13.25,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.425,5.369674158461538,6.314348316923077,7.259022475384615,8.203696633846153,9.148370792307691,10.09304495076923,11.037719109230768,11.982393267692306,12.927067426153844,13.871741584615382,14.81641574307692,15.761089901538462,{"y":16.70576406,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.425,5.211859923076923,5.998719846153846,6.785579769230768,7.572439692307691,8.359299615384614,9.146159538461538,9.93301946153846,10.719879384615384,11.506739307692307,12.29359923076923,13.080459153846153,13.867319076923074,{"y":14.654179,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.425,5.099135469230769,5.773270938461538,6.447406407692307,7.121541876923077,7.795677346153846,8.469812815384614,9.143948284615384,9.818083753846153,10.492219223076923,11.166354692307692,11.840490161538462,12.514625630769231,{"y":13.1887611,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.267,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.816,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.354,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.619,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.959,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.844,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.298,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.442,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.425,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.71

Average Price Target€14.65

Lowest Price Target€13.19

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Chico

Wedbush

€16.71

Buy

274.57%

Upside

Reiterated

07/13/26

Ardelyx (ARDX) Receives a Buy from Wedbush

Dennis Ding

Jefferies

€13.19

Buy

195.71%

Upside

Reiterated

06/26/26

Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'

Caroline Palomeque

Ladenburg Thalmann & Co.

€14.07

Buy

215.43%

Upside

Initiated

06/16/26

Ardelyx assumed with a Buy at LadenburgArdelyx assumed with a Buy at Ladenburg

Allison Bratzel

Piper Sandler

€14.07

Buy

215.43%

Upside

Reiterated

05/01/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)

Matthew Caufield

H.C. Wainwright

€15.83

Buy

254.85%

Upside

Reiterated

05/01/26

Analyst Reiterates Buy on Ardelyx, Citing Tenapanor Momentum and Pipeline Upside with Unchanged $18 Price Target

Joseph Thome

TD Cowen

€11.43

Buy

156.28%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Ardelyx (NASDAQ: ARDX) and Summit Therapeutics (NASDAQ: SMMT)

Julian Harrison

BTIG

€14.95

Buy

235.14%

Upside

Reiterated

02/20/26

Ardelyx (ARDX) Receives a Buy from BTIG

Yigal Nochomovitz

Citi

€9.67→€12.31

Buy

176.00%

Upside

Reiterated

01/08/26

Ardelyx price target raised to $14 from $11 at CitiArdelyx price target raised to $14 from $11 at Citi

Christopher Raymond

Raymond James

€14.07→€16.71

Buy

274.57%

Upside

Reiterated

01/08/26

Ardelyx price target raised to $19 from $16 at Raymond JamesArdelyx price target raised to $19 from $16 at Raymond James

Louise Chen

Scotiabank

€13.19

Buy

195.71%

Upside

Reiterated

08/05/25

Scotiabank Sticks to Its Buy Rating for Ardelyx (ARDX)

Roanna Ruiz

Leerink Partners

€8.79→€9.67

Buy

116.86%

Upside

Reiterated

08/05/25

Ardelyx's Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Chico

Wedbush

€16.71

Buy

274.57%

Upside

Reiterated

07/13/26

Ardelyx (ARDX) Receives a Buy from Wedbush

Dennis Ding

Jefferies

€13.19

Buy

195.71%

Upside

Reiterated

06/26/26

Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'

Caroline Palomeque

Ladenburg Thalmann & Co.

€14.07

Buy

215.43%

Upside

Initiated

06/16/26

Ardelyx assumed with a Buy at LadenburgArdelyx assumed with a Buy at Ladenburg

Allison Bratzel

Piper Sandler

€14.07

Buy

215.43%

Upside

Reiterated

05/01/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)

Matthew Caufield

H.C. Wainwright

€15.83

Buy

254.85%

Upside

Reiterated

05/01/26

Analyst Reiterates Buy on Ardelyx, Citing Tenapanor Momentum and Pipeline Upside with Unchanged $18 Price Target

Joseph Thome

TD Cowen

€11.43

Buy

156.28%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Ardelyx (NASDAQ: ARDX) and Summit Therapeutics (NASDAQ: SMMT)

Julian Harrison

BTIG

€14.95

Buy

235.14%

Upside

Reiterated

02/20/26

Ardelyx (ARDX) Receives a Buy from BTIG

Yigal Nochomovitz

Citi

€9.67→€12.31

Buy

176.00%

Upside

Reiterated

01/08/26

Ardelyx price target raised to $14 from $11 at CitiArdelyx price target raised to $14 from $11 at Citi

Christopher Raymond

Raymond James

€14.07→€16.71

Buy

274.57%

Upside

Reiterated

01/08/26

Ardelyx price target raised to $19 from $16 at Raymond JamesArdelyx price target raised to $19 from $16 at Raymond James

Louise Chen

Scotiabank

€13.19

Buy

195.71%

Upside

Reiterated

08/05/25

Scotiabank Sticks to Its Buy Rating for Ardelyx (ARDX)

Roanna Ruiz

Leerink Partners

€8.79→€9.67

Buy

116.86%

Upside

Reiterated

08/05/25

Ardelyx's Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

3 Months

Yigal NochomovitzCiti

Success Rate

9/17 ratings generated profit

Average Return

+27.72%

Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +27.72% per trade.

1 Year

Christopher RaymondRaymond James

Success Rate

8/16 ratings generated profit

Average Return

+26.47%

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +26.47% per trade.

2 Years

Yigal NochomovitzCiti

Success Rate

8/17 ratings generated profit

Average Return

+90.16%

Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +90.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

41X Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 41X has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 41X average Analyst price target in the past 3 months is 14.65.

Each month's total comprises the sum of three months' worth of ratings.

41X Financial Forecast

41X Earnings Forecast

Next quarter’s earnings estimate for 41X is -€0.05 with a range of -€0.08 to -€0.03. The previous quarter’s EPS was -€0.13. 41X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Sales Forecast

Next quarter’s sales forecast for 41X is €105.53M with a range of €97.55M to €110.68M. The previous quarter’s sales results were €81.94M. 41X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Stock Forecast FAQ

What is DE:41X’s average 12-month price target, according to analysts?

Based on analyst ratings, Ardelyx’s 12-month average price target is 14.65.

What is DE:41X’s upside potential, based on the analysts’ average price target?

Ardelyx has 228.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ardelyx a Buy, Sell or Hold?

Ardelyx has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ardelyx’s share price target?

The average share price target for Ardelyx is 14.65. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.71 ,and the lowest forecast is €13.19. The average share price target represents 228.57% Increase from the current price of €4.46.

What do analysts say about Ardelyx?

Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Ardelyx?

To buy shares of DE:41X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ardelyx (41X) Stock Forecast & Price Target

41X Analyst Ratings

41X Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ardelyx

41X Analyst Recommendation Trends

41X Financial Forecast

41X Earnings Forecast

41X Sales Forecast

41X Stock Forecast FAQ

Detailed List of Analyst Forecasts